Skip to main content
Premium Trial:

Request an Annual Quote

Iconix Signs on Eisai as a Customer for Chemogenomics Profiling Services

NEW YORK, April 14 - Iconix pharmaceuticals has signed on Japanese pharma Eisai Co. as a service customer for its chemogenomic profiling and analytical services, the company said today.


Under the agreement, Iconix and Eisai will use Iconix' DrugMatrix chemogenomics system to evaluate Eisai's early-stage drug candidates. Specifically, Eisai hopes to gain an understanding of the toxicology, off-target effects, and mechanism of action in compounds.


Iconix, of Mountain View, Calif., has developed its DrugMatrix system along with MDS Pharma and Incyte, and has integrated its tools with Spotfire's visualization capabilities.


The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.